ProQR Receives FDA Fast Track Designation for QR-110 For Leber’s Congenital Amaurosis Type 10

The FDA granted a Fast Track designation to ProQR’s QR-110, for patients with Leber’s Congenital Amaurosis Type 10.

LCA 10 leads to progressive loss of vision causing most patients to lose their sight in the first few years of life. QR-110 is administered through intravitreal injections in the eye.

The drug candidate was previously granted orphan designations in the U.S. and the European Union.